Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Repare Therapeutics price target raised to $45 from $40 at Northland » 08:25
11/18/21
11/18
08:25
11/18/21
08:25
RPTX

Repare Therapeutics

$27.16 /

-0.845 (-3.02%)

Northland analyst Tim…

Northland analyst Tim Chiang raised the firm's price target on Repare Therapeutics to $45 from $40 and keeps an Outperform rating on the shares after having hosted a Synthetic Lethality Biotech Conference with a number of the company's senior executives and researchers where Repare's SNIPRx screening technology platform and key pipeline candidates were highlighted. Coming out of the event, he sees the company having leading research capabilities and thinks the longer-term growth prospects are "significant," Chiang said.

ShowHide Related Items >><<
RPTX Repare Therapeutics
$27.16 /

-0.845 (-3.02%)

RPTX Repare Therapeutics
$27.16 /

-0.845 (-3.02%)

11/10/21 Stifel
Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report
09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
RPTX Repare Therapeutics
$27.16 /

-0.845 (-3.02%)

  • 28
    Oct
Conference/Events
Northland to hold a virtual conference » 10:37
11/17/21
11/17
10:37
11/17/21
10:37
IDYA

Ideaya Biosciences

$23.93 /

+0.05 (+0.21%)

, RPTX

Repare Therapeutics

$27.47 /

-0.53 (-1.89%)

Synthetic Lethality…

Synthetic Lethality Virtual Conference to be held on November 17. Webcast Link

ShowHide Related Items >><<
RPTX Repare Therapeutics
$27.47 /

-0.53 (-1.89%)

IDYA Ideaya Biosciences
$23.93 /

+0.05 (+0.21%)

IDYA Ideaya Biosciences
$23.93 /

+0.05 (+0.21%)

09/22/21 Stifel
Ideaya Biosciences initiated with a Hold at Stifel
06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
RPTX Repare Therapeutics
$27.47 /

-0.53 (-1.89%)

11/10/21 Stifel
Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report
09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
RPTX Repare Therapeutics
$27.47 /

-0.53 (-1.89%)

IDYA Ideaya Biosciences
$23.93 /

+0.05 (+0.21%)

  • 28
    Oct
  • 08
    Jul
IDYA Ideaya Biosciences
$23.93 /

+0.05 (+0.21%)

Recommendations
Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report » 16:30
11/10/21
11/10
16:30
11/10/21
16:30
RPTX

Repare Therapeutics

$26.83 /

+0.66 (+2.52%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett lowered the firm's price target on Repare Therapeutics to $47 from $48 and keeps a Buy rating on the shares after what he called "a quiet 3Q21 print." His biggest takeaway from the company's initial RP-3500 update is that there are a number of patients who remain on therapy at a dose that's seems tolerable and he looks toward updates around RP-3500 and RP-6306 next year as "good catalysts," the analyst said.

ShowHide Related Items >><<
RPTX Repare Therapeutics
$26.83 /

+0.66 (+2.52%)

RPTX Repare Therapeutics
$26.83 /

+0.66 (+2.52%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$26.83 /

+0.66 (+2.52%)

  • 28
    Oct
Earnings
Repare Therapeutics reports Q3 EPS (83c), consensus (71c) » 07:37
11/10/21
11/10
07:37
11/10/21
07:37
RPTX

Repare Therapeutics

$26.10 /

-0.93 (-3.44%)

Reports Q3 revenue…

Reports Q3 revenue $278,000, consensus $140,000. "We are pleased with the progress we've made this quarter in our Phase 1 part of the RP-3500 program, including the comprehensive safety data and emerging evidence of activity from the TRESR study which was part of the featured oral presentation at the AACR-NCI-EORTC conference this year," said Lloyd Segal, president and CEO of Repare. "The findings continue to suggest RP-3500 may have broad clinical efficacy in tumors with diverse genetic alterations and provides further clinical proof of concept and validation of our SNIPRx platform. We look forward to providing updates in the future on the potential of RP-3500, both as a monotherapy and in combination with PARP inhibitors."

ShowHide Related Items >><<
RPTX Repare Therapeutics
$26.10 /

-0.93 (-3.44%)

RPTX Repare Therapeutics
$26.10 /

-0.93 (-3.44%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$26.10 /

-0.93 (-3.44%)

  • 28
    Oct
Earnings
Repare Therapeutics reports Q3 EPS (83c), consensus (71c) » 07:28
11/10/21
11/10
07:28
11/10/21
07:28
RPTX

Repare Therapeutics

$26.10 /

-0.93 (-3.44%)

Reports Q3 revenue $278K,…

Reports Q3 revenue $278K, consensus $140K. presentation at the AACR-NCI-EORTC conference this year," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "The findings continue to suggest RP-3500 may have broad clinical efficacy in tumors with diverse genetic alterations and provides further clinical proof of concept and validation of our SNIPRx platform. We look forward to providing updates in the future on the potential of RP-3500, both as a monotherapy and in combination . Cash and cash equivalents, restricted cash and marketable securities as of September 30, 2021 were $268.2 million, exclusive of the proceeds from the follow-on public offering.

ShowHide Related Items >><<
RPTX Repare Therapeutics
$26.10 /

-0.93 (-3.44%)

RPTX Repare Therapeutics
$26.10 /

-0.93 (-3.44%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$26.10 /

-0.93 (-3.44%)

  • 28
    Oct
Over a month ago
Syndicate
Repare Therapeutics 4M share Spot Secondary; price range $22.00-$undefined » 21:21
10/27/21
10/27
21:21
10/27/21
21:21
RPTX

Repare Therapeutics

$23.47 /

+0.3 (+1.29%)

The deal size was…

The deal size was increased to $88M in common stock from $75M. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as joint book running managers for the offering.

ShowHide Related Items >><<
RPTX Repare Therapeutics
$23.47 /

+0.3 (+1.29%)

RPTX Repare Therapeutics
$23.47 /

+0.3 (+1.29%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$23.47 /

+0.3 (+1.29%)

  • 28
    Oct
Syndicate
Repare Therapeutics files to sell $75M in common stock » 16:01
10/27/21
10/27
16:01
10/27/21
16:01
RPTX

Repare Therapeutics

$23.57 /

+0.395 (+1.70%)

Morgan Stanley, Goldman…

Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
RPTX Repare Therapeutics
$23.57 /

+0.395 (+1.70%)

RPTX Repare Therapeutics
$23.57 /

+0.395 (+1.70%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$23.57 /

+0.395 (+1.70%)

Conference/Events
Repare Therapeutics to host investor day » 16:25
10/08/21
10/08
16:25
10/08/21
16:25
RPTX

Repare Therapeutics

$20.43 /

-1.44 (-6.58%)

Investor Day to be held…

Investor Day to be held on October 8 at 5 pm. Webcast Link

ShowHide Related Items >><<
RPTX Repare Therapeutics
$20.43 /

-1.44 (-6.58%)

RPTX Repare Therapeutics
$20.43 /

-1.44 (-6.58%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$20.43 /

-1.44 (-6.58%)

Hot Stocks
Repare Therapeutics presents preliminary data from Phase 1/2 TRESR trial » 15:13
10/08/21
10/08
15:13
10/08/21
15:13
RPTX

Repare Therapeutics

$23.79 /

+1.92 (+8.78%)

Repare Therapeutics…

Repare Therapeutics announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Data presented in the abstract reflect the monotherapy cohort at data cutoff of June 4, 2021 and include 62 patients, while data presented at the conference reflect a data cutoff of August 15, 2021 and include 101 patients. Highlights from the data presented at the AACR-NCI-EORTC conference include: RP-3500 appears safe and well tolerated. The most common treatment emergent adverse events in any of the 101 patients treated, expectedly, was grade 1-2 anemia, with only 21.8% of all patients experiencing Grade 3 anemia, and only 14.5% of those patients treated on the recommended weekly schedule of 3 days on/4 days off. There were no discontinuations related to RP-3500 emergent adverse events and dose interruptions, reductions or red blood cell transfusions were infrequent on the recommended 3 days on/4 days off regimen. Recommended Phase 2 dose and schedule for further monotherapy RP-3500 evaluation is 160mg, taken weekly for 3 days on and 4 days off. This schedule assures repeated weekly exposure to RP-3500 at an efficacious dose. Antitumor activity was observed in patients with tumors harboring SNIPRX predicted genomic alternations at doses greater than100mg, across multiple tumor types and included patients after PARP inhibitor failure. Meaningful clinical benefit was observed in 49% of 69 patients with available scans. Those include 12 patients with tumor responses per established international efficacy criteria, 14 patients with ongoing stable disease for at least 16 weeks and 8 patients with stable disease who only had two radiological evaluations, but had demonstrated significant decreases in tumor markers and tumor shrinkage of less than 30%. Promising deep molecular responses in circulating tumor DNA for tumors with STEP2 genomic alterations were observed in the initial set of patients available for serial ctDNA analysis. "We are very pleased that these data suggest RP-3500 may have a best-in-class profile as a potent and highly selective ATR inhibitor and represent compelling validation for the ability of our SNIPRx platform and our STEP2 process to improve efficacy through molecular selection of tumors. We look forward to the imminent expansion of the TRESR study in a range of genotypes and, continuing and broadening our combination therapy studies, including with a range of PARP inhibitors and gemcitabine," said Lloyd Segal, President and CEO of Repare.

ShowHide Related Items >><<
RPTX Repare Therapeutics
$23.79 /

+1.92 (+8.78%)

RPTX Repare Therapeutics
$23.79 /

+1.92 (+8.78%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$23.79 /

+1.92 (+8.78%)

Conference/Events
Repare Therapeutics to host investor day » 09:55
10/08/21
10/08
09:55
10/08/21
09:55
RPTX

Repare Therapeutics

$23.05 /

+1.18 (+5.40%)

Investor Day to be held…

Investor Day to be held on October 8 at 5 pm. Webcast Link

ShowHide Related Items >><<
RPTX Repare Therapeutics
$23.05 /

+1.18 (+5.40%)

RPTX Repare Therapeutics
$23.05 /

+1.18 (+5.40%)

09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
06/28/21 Guggenheim
Repare Therapeutics initiated with a Buy at Guggenheim
03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
RPTX Repare Therapeutics
$23.05 /

+1.18 (+5.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.